AstraZeneca disinvest hypertension medicines to Atnahs Pharma
AstraZeneca divest its global commercial rights of Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide... Read More
AstraZeneca to launch QTERN in India with DCGI marketing authorization approval
Posted on27 Sep 2019
Comments0
AstraZeneca Pharma has received import and market permission in Form 45 (marketing authorization) for QTERN (fixed dose combination of dapagliflozin 10mg +... Read More
AstraZeneca’s Lynpraza got DCGI (India) marketing approval
AstraZeneca Pharma India has received Import & Market permission for olaparib (Lynparza )100 mg and 150 mg tablets in India by the... Read More
Geisinger, AstraZeneca partner to create new asthma app suite
Geisinger, an integrated health services organization, and AstraZeneca have partnered to improve asthma care by creating a suite of products that integrate... Read More
AstraZeneca launches once-daily Xigduo XR tablets for comprehensive management of type 2 diabetes in India
AstraZeneca Pharma India Limited (AstraZeneca India) has announced the launch of its innovative anti-diabetic combination once-daily therapy Xigduo XR for treatment of... Read More
Pharma Strategy Lookouts: Dizal Pharmaceutical, JV of AstraZeneca in China
Posted on28 Nov 2017
TagsAstraZenca, Dapagliflozin, Dizal Pharmaceutical, Farxiga, osimertinib, SGLT-2 inhibitor, Tagrisso, Type 2 Diabetes
Comments0
AstraZeneca today announced a strategic joint venture with the Chinese Future Industry Investment Fund (FIIF) to form an equally-owned, stand-alone company in China... Read More